Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’

Also Addresses Insulin Aspart CRL From FDA On Rival To NovoLog

 
• By Anju Ghangurde
  
accelerate
Glargine Opportunity Builds Up For Biocon • Source: Alamy

More from Earnings

More from Business